14TH ANNUAL MIAMI CANCER MEETING (MCM):
“From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!”

January 20-22, 2017
Conrad Hilton Hotel
Miami, Florida
Educational Committee

Jumana Ashy, M.S, Pharm.D
Eileen Butler, RN, MSN, OCN, CPHON, BMTCN
Gerardo Colon-Otero, MD
Dina Dumercy, Pharm.D., BCOP
Primo Lara, M.D.
Jessica MacIntyre, ARNP, NP-C
Eduardo Sotomayor, MD

Distinguished Faculty

Jaffer A. Ajani, M.D.
Professor, Department of Gastrointestinal (GI) Medical Oncology,
Division of Cancer Medicine,
Professor, Department of Epidemiology,
Division of OVP, Cancer Prevention and Population Sciences
The University of Texas MD Anderson Cancer Center
Houston, TX

Scott J. Antonia, M.D., Ph.D.
Department Chair of the Thoracic Oncology Department
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Professor of Oncologic Sciences
University of South Florida College of Medicine
Tampa, FL

Denisse Bretel, MD
Medical Director,
GECO (Peruvian Oncology Research Group)
Lima, Peru

Eileen Butler, RN, MSN, OCN, CPHON, BMTCN
University of Miami Miller School of Medicine
Miami, FL

Gerardo Colon-Otero, M.D.
Associate Professor of Medicine
Mayo Clinic College of Medicine
Mayo Clinic, Jacksonville, FL

Dina Dumercy, Pharm.D., BCOP
Clinical Coordinator Oncology
Memorial Cancer Institute
Pharmacy Department
Memorial Healthcare System
Hollywood, FL

Barbara J. Gilitz, M.D.
Associate Professor of Medicine,
USC Keck School of Medicine
Los Angeles, CA

Sergio A. Giralt, M.D.
Chief, Adult Bone Marrow Transplant Service;
Melvin Berlin Family Chair in Multiple Myeloma
Memorial Sloan Kettering Cancer Center
New York, NY

Brian Hunis, M.D.
Director of Head & Neck Cancer and Quality
Memorial Cancer Institute
Clinical Associate Professor of Medicine
Herbert Wertheim College of Medicine
Florida International University
Hollywood, FL

Alan Koletsky, M.D.
Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Genitourinary Cancer Research Program
Lynn Cancer Institute
Boca Raton, FL

Primo N. Lara, Jr., M.D.
Professor of Medicine, UC Davis School of Medicine
Acting Director, UC Davis Comprehensive Cancer Center
Sacramento CA

Jose Lutzky, M.D.
Co-Chief, Hematology & Oncology
Director, Mount Sinai Melanoma Program
Mount Sinai Medical Center
Miami, FL

Jessica MacIntyre, ARNP, NP-C
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Miami, FL

Eríbeto Marques Jr., M.D.
Medical Director of Santa Agueda Hospital
Department of Medical Oncology
Member of SBOC/SLACOM
Recife-PE, Brazil

Taofeek K Owonikoko, M.D., Ph.D.
Director, Thoracic Oncology Program
Assistant Professor
Emory School of Medicine
Atlanta, GA

Luis E. Raez, M.D, FACP, FCCP
Chief of Hematology-Oncology &
Medical Director Memorial Cancer Institute
Memorial Health Care System
Clinical Associate Professor of Medicine
Herbert Wertheim College of Medicine
Florida International University
Miami, Florida

Caio Max S. Rocha Lima, M.D.
Hematology and Oncology
Associate Cancer Center Director for Translational Research
Gibbs Cancer Center & Research Institute
CMO Guardian Research Network
Spartanburg Healthcare System
Spartanburg, SC

Christian Rolfo Cervetto, M.D., PhD
Head of Unit Phase I - Early Clinical Trials
Director of Clinical Trial Management Program
Oncology Department University Hospital
Antwerp, Belgium

Hope Rugo, M.D.
Professor of Medicine, Breast Oncology and Clinical Trials Education University of California
San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Edgardo S. Santos Castillero, M.D., FACP
Medical Director of Cancer Research
Lynn Cancer Institute
Thoracic and Head and Neck Cancer Programs
Associate Professor of Clinical Biomedical Sciences
Florida Atlantic University
Boca Raton, Florida

Eduardo Sotomayor, M.D.
Director, George Washington University Cancer Center
Professor of Medicine, George Washington University School of Medicine & Health Sciences
Washington, DC

Martin S. Tallman M.D.
Chief of Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Vicente Valero, M.D.
Professor, and Deputy Chairman,
Breast Medical Oncology Department
Clinical Director, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic
Associate Director, Nellie B. Connally Breast Cancer Research Program
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Adrienne M. Vazquez, MSN, ACNP-BC, AOCN
Memorial Sloan Kettering Cancer Center
New York, NY

CONFERENCE DESCRIPTION

Presentations from latest national (AACR 2016, ASCO 2016 etc.) on the state-of-the-art for cancer management are delivered by invited faculty. From clinical, translational, and population-based research, the faculty will guide attendees through a series of cutting edge lectures that will cover all major cancer types. The objective is to understand the latest advances in cancer treatment (that includes radiation therapy and surgery) is developed but also engage in personal interaction with our panel and understand the state-of-the-art management in cancer treatment.

The areas of focus for this conference include but are not limited to:

- New immunotherapeutic agents.
- Chemotherapeutic agents, new antiangiogenic agents and their combinations.
- Treatment of bone metastasis, malignant hypercalcemia, and management of paraneoplastic syndromes.
- Development in cancer management. Residents in training, nurse practitioners (ARNP), oncology nurses, registered nurses, oncologists, physician assistants (PA), advanced registered nurses, and medical oncologists will benefit from presentations and discussions of cancer management and new developments in oncology.

Upon completion of this course attendees will be able to:

- Understand the latest advances in chemotherapy, targeted therapy, and immunotherapy.
- Understand the latest advances in the management of hematological and solid malignancies.
- Understand the latest advances in the management of hematological and solid malignancies related to side effects.

The Medical Educator Consortium, designates this live activity for a maximum of 15.0 AMA PRA Category 1 Credit(s)™.
CONFERENCE DESCRIPTION

This is a three-day conference designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician assistants (PA), advanced registered nurse practitioners (ARNP), oncology nurses, registered pharmacists, pharmacy technicians, and radiation therapists. General practitioners (internal medicine and family medicine) will have the benefit of review standard of care and new developments in cancer management. Residents in training and fellows from these specialties are encouraged to attend.

This year, a depth discussion in immunotherapy for multiple tumor types will take place. Immunotherapy in Oncology is changing the landscape of therapy for different solid tumors such as lung cancer, bladder, kidney, melanoma, and others. Also, topics in solid tumors and hematological malignancies such as breast cancer, lung cancer, gastrointestinal (GI) malignancies, genitourinary (GU) cancers, gynecologic malignancies, head and neck cancers, melanoma, multiple myeloma, CLL and non-Hodgkin’s lymphoma, and myelodysplastic syndrome will be reviewed. There will also be a special session devoted to the area of supportive care in oncology, with emphasis on bone metastasis, malignant hypercalcemia, and management of chemotherapy, targeted therapy and immunotherapy-related side effects. The areas of focus for this conference will include the current standards of care in the treatment of all aforementioned malignancies and new developments in these areas of cancer care. There will be much emphasis on molecular diagnosis and individualization of cancer therapy based on molecular profiles. There will be reviews of new chemotherapeutic agents, new antiangiogenic agents and new immunotherapeutic agents.

Presentations from latest national (AACR 2016, ASCO 2016 and ASH 2016) and international forums (ESMO 2016 and WCLC 2016) meetings will be discussed and guidelines of cancer care will be emphasized. The participants in the meeting will have the opportunity not only to learn, review, and understand the state-of-the-art management in cancer care but also engage in personal interaction with our panel of experts in these subjects during our question and answer sessions.

CONFERENCE OBJECTIVES

Upon completion of this course attendees will be able to:

1) Understand the latest advances in chemotherapy, targeted therapy and immunotherapy options available for lung cancer, breast cancer, GI malignancies, GU malignancies, melanoma, brain tumors, head and neck cancer as well as hematological malignancies including multiple myeloma, NHL, MDS, and CLL.

2) Evaluate the current standards of care in the treatment of a variety of solid and hematologic malignancies.

3) Discuss risks and benefits when combined modality of treatment (that includes radiation therapy and surgery) is delivered to patients who have localized malignant processes (i.e., NSCLC, head and neck, prostate cancer, and others).

4) Management of adverse events from the use of novel immunotherapy and targeted therapy agents.

5) Management of complications and symptoms induced by chemotherapy, immunotherapy or targeted therapy including nausea, vomiting, hematologic toxicities (e.g., anemia, neutropenia) and others.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURS (CME)

The Medical Educator Consortium designates this live activity for a maximum of 15.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

NURSING CEU

Continuing Education Credit for Nurses will be awarded by the University of Miami Nursing Education Department. A total of 15 CEU’s will be awarded for attendance to all three days of the conference. Participants may attend separately on Friday for 2.1 credit hours, Saturday for 8.4 credit hours, and Sunday 4.5. A certificate of completion will be provided to each participant at the end of the conference. Credit will be entered into CE Broker.

PHARMACY CEU

This activity is approved for a total of 15 contact hours of Continuing Education Credit for Pharmacists and Pharmacy Technicians awarded by the University of Miami Sylvester Comprehensive Cancer Center. Participants must attend all day lectures to receive credit for that day. Partial credits are not available. Where credits are approved on a session-by-session basis, participants must attend each session in its entirety to receive complete credit for the session. A certificate of completion will be provided to each participant at the end of the conference. Credit will be entered into CE Broker. UMHC/Sylvester is a approved by the Florida Board of Pharmacy as a provider of continuing pharmacy education. “Partial Credit are available”.

FACULTY DISCLOSURE STATEMENT

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the educational activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.
**14th Annual Miami Cancer Meeting (MCM): “New From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!”**

**PROGRAM AGENDA**

**Friday, January 20, 2017**

**Registration & Visit Exhibits**

Welcome and Introduction  
Luis E. Raez

**Supportive Care and Palliative Therapy Session**

Management of Immunotherapy-Induced Disorders  
(pneumonitis, colitis, thyroid disorders, skin rash, and others).  
Adrienne Vazquez

Cancer Therapy-Induced Bone Loss and Malignant Hypercalcemia.  
Eriberto Marques, Jr.

Nausea and Vomiting: Novel advances in Emesis Management.  
Jessica MacIntyre

Keynote Speaker: The Evolution of Lung Cancer Therapy in the Last Decade: “From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!”

Christian Rolfo

Round Table Discussion and Q & A Session.  
Speakers: MacIntyre, Vazquez, Marques, and Rolfo.

**Dinner & Learn Symposia (non CME)**

**Saturday, January 21, 2017**

**Registration & Visit Exhibits**

**Breakfast & Learn Symposium (non CME)**

**Immunotherapy Session 1**

**Malignant Diseases: The New Targets of Immunotherapy.**

Immunotherapy in Lung Cancer. 
Scott Antonia

Immunotherapy in Genitourinary Cancers.  
Alan Koletsky

Immunotherapy in Melanoma.  
Jose Lutzky

**Coffee Break & Visit Exhibits**

**Immunotherapy Session 2**

**Malignant Diseases: The New Targets of Immunotherapy.**

Immunotherapy in Head and Neck Cancer.  
Edgardo S. Santos

Immunotherapy in Breast and Gynecologic Malignancies.  
Gerardo Colon-Otero

Is it PDL-1 the Biomarker? Mutation Burden? Or What is the Best Biomarker for Lung Cancer Immunotherapy?  
Taofek Owonikoko

Round Table Discussion and Q & A Session.  
Speakers: Santos, Colon-Otero, Owonikoko and Hunis

**Lunch & Learn Symposia (non-CME)**

**Coffee Break and Visit Exhibits**
PROGRAM AGENDA

2:20 pm – 4:00 pm
Genitourinary Malignancy Session
Moderator: Edgardo S. Santos
Primo N. Lara, Jr.

2:20 pm – 3:00 pm
Tyrosine Kinase Inhibitors and Other Pathways in Renal Cell Carcinoma.

3:00 pm – 3:40 pm
Novel Pathways and Genomics in the Management of Prostate Cancer.

3:40 pm – 5:00 pm
Round Table Discussion and Q & A Session.

4:00 pm – 5:40 pm
Coffee Break & Visit Exhibits

5:30 pm – 6:00 pm
Immunotherapy and Targeted Therapy in Multiple Myeloma.
Sergio Giralt

5:00 pm – 5:30 pm
Eduardo M. Sotomayor

5:30 pm – 6:00 pm
High Risk Myelodysplasia and Acute Leukemias.
Martin Tallman

Round Table Discussion and Q & A Session.
Speakers: Giralt, Sotomayor, Tallman

Sunday, January 22, 2017

Registration & Visit Exhibits

Breakfast & Learn Symposia (non CME)

Gastrointestinal Malignancy Session
Moderator: Caio Max Rocha-Lima

8:40 am – 9:00 am
Novel Advances in Treatment of Gastric Cancers and Pancreatobiliary Malignancies.
Caio Max Rocha Lima

8:40 am – 9:10 am
Genomics and New Insights of Colorectal Cancer.
Jaffe Ajani

9:10 am – 9:40 am
Round Table Discussion and Q & A session
Speakers: Ajani and Rocha-Lima

9:40 am – 9:50 am
Thyroid Malignancies.
Brian Hunis

9:50 am – 10:20 am
Coffee Break & Visit Exhibits

10:20 am – 10:40 am
Lung Cancer Session
Moderator: Edgardo S. Santos

10:40 am – 12:00 pm
EGFR, ALK and ROS-1 in Lung Cancer.
Luis E. Raez

10:40 am – 11:00 am
Other Novel Pathways in Lung Cancer (MET, RET, NTRK, BRAF) and Antiangiogenic Agents.
Barbara Gitlitz

11:10 am – 11:40 am
Where are we now in Squamous-NSCLC and Small Cell Lung Cancer?
Primo Lara, M.D.

11:40 am – 12:10 pm
Round Table Discussion and Q & A Session.
Speakers: Gitlitz, Raez & Santos

12:10 pm – 12:30 pm
Lunch & Learn Symposia

12:30 pm – 1:40 pm
Breast Cancer Section
Moderator: Denisse Bretel

1:40 pm – 3:15 pm
Anti-HER2 Therapies in Breast Cancer: Adjuvant and Neoadjuvant.
Hope Rugo

1:40 pm – 2:20 pm
Chemotherapy and Hormonal Therapy in the Metastatic Setting. (non Her2 therapy)
Vicente Valero

2:20 pm – 3:00 pm
Round Table Discussion and Q & A Session.
Speakers: Rugo, Valero, and Bretel

3:00 pm – 3:10 pm
Meeting Adjourn and Closing Remarks
HOTEL INFORMATION

The Conrad Hilton Hotel Miami
1395 Brickell Avenue
Miami, FL 33131
Telephone: 305-503-6585
Website: http://conradhotels1.hilton.com

Discover the luxury of the Conrad Miami, the premier hotel in South Florida, combining the ultimate hotel service and the latest technological advancements with the fashion sensibilities of downtown Miami. Located in the innovatively designed structure of concave glass and steel, in the heart of the city’s financial district, the Conrad Miami hotel overlooks Biscayne Bay in Florida. The Conrad Miami has quick and easy access to many attractions in downtown Miami, including South Beach, Coconut Grove and Key Biscayne and is also just 15 minutes from the Miami International Airport.

The hotel is offering special rates during this conference of $315 Deluxe City View; $345 Deluxe Bay View plus tax, European plan (no meals). The cut of date to make reservations is January 4, 2017, after this date reservations are subject to hotel availability.

Make your reservations by calling 1-800-CONRADS and identify you as attending the “Miami Cancer Meeting” group code “AMC” or using the link https://resweb.passkey.com/go/MCM2017

REGISTRATION FORM

14th Annual Miami Cancer Meeting (MCM):
“From Chemotherapy to Targeted Therapy, Immunotherapy and Beyond!”
January 20-22, 2017
Conrad Hilton Hotel, Miami, FL

Register online at www.meccinc.com or FAX to 305/675-2718.

Name ____________________________________________ Degree __________________________

Address __________________________________________

City ____________________________________________ State __________ Zip ______________

Telephone (___) __________________ Fax (___) __________________

Email address __________________________________________

Specialty __________________________________________

Type of Practice:  □ Private  □ Academic  □ Hospital  □ Resident/Fellow

Registration fee:
$250 - Physicians
$100 - Residents, Fellows, Nurses & Allied Health Professionals
$300 - Industry Professionals

Enclosed is my check in the i/a/o of _____ for registration of this course.

I authorize MECC to charge my credit card i/a/o $______ for registration of this course using the following credit card.

Name on Card ____________________________________________ Exp. Date ________________

Card number ____________________________________________ CVV ________________

Authorized signer _______________________________________

If you require special assistance or have specific dietary requirements, please contact MECC, Inc. no later than January 4th, 2017 via email at tvalls@meccinc.com.